CHRS Profile
Coherus BioSciences, Inc., headquartered in Redwood City, California, is a biopharmaceutical company specializing in the development, commercialization, and production of biosimilars and immuno-oncology therapies. Established in 2010 and formerly known as BioGenerics, Inc., Coherus is a key player in the biosimilars market, particularly in the United States. The company’s flagship product, UDENYCA, is a biosimilar to Neulasta, a long-acting granulocyte-stimulating colony factor, used to reduce the risk of infection in cancer patients undergoing chemotherapy.
Coherus’s pipeline includes a range of biosimilars targeting high-value therapeutic areas. The company is advancing biosimilars of major biologics such as Humira, Avastin, and Lucentis, aiming to provide cost-effective alternatives to these widely used therapies. In addition to its biosimilars portfolio, Coherus is developing Toripalimab, a novel anti-PD-1 antibody currently in clinical trials in China for the second-line treatment of melanoma. The company also has a biosimilar candidate for Bevacizumab and CHS-1420, an adalimumab biosimilar targeting anti-TNF treatment.
Coherus BioSciences maintains strategic collaborations and license agreements with several key industry players, including Selexis SA, AbbVie, Pfizer, Bioeq AG, Innovent Biologics, and Junshi Biosciences. These partnerships enhance Coherus's ability to develop and commercialize its biosimilar and novel therapeutic products, leveraging advanced technologies and broadening its market reach.
With a focus on innovation and strategic partnerships, Coherus BioSciences is committed to addressing unmet medical needs through its diverse portfolio of biosimilars and immuno-oncology agents. The company's ongoing research and development efforts are aimed at delivering high-quality, affordable treatments to patients and supporting the broader biopharmaceutical landscape.
|
